1
|
Kontogiannis S, Markantes G, Stamou M, Tsagkarakis M, Mamali I, Giannitsas K, Perimenis P, Georgopoulos N, Athanasopoulos A. Anti-Müllerian hormone: a novel biomarker for aggressive prostate cancer? Emerging evidence from a prospective study of radical prostatectomies. Hormones (Athens) 2024; 23:297-304. [PMID: 38127275 PMCID: PMC11190032 DOI: 10.1007/s42000-023-00520-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 12/11/2023] [Indexed: 12/23/2023]
Abstract
PURPOSE Prostate cancer patients are a heterogeneous group as regards the aggressiveness of the disease. The relationship of steroid hormones with the aggressiveness of prostate cancer is unclear. It is known that the anti-Müllerian hormone (AMH) inhibits prostate cancer cell lines in vitro. The aim of this study is to investigate the relationship of AMH and steroid hormones with the aggressiveness of prostate cancer. METHODS This was a prospective study of consecutive radical prostatectomy patients. We measured the following hormones: total testosterone, sex hormone-binding globulin, albumin, luteinizing hormone, follicle-stimulating hormone, estradiol, dehydroepiandrosterone sulfate, androstenedione, and AMH. The minimum follow-up after radical prostatectomy was 5 years. For the aggressiveness of prostate cancer, we considered the following three variables: post-operative Gleason score (GS) ≥ 8, TNM pΤ3 disease, and prostate-specific antigen (PSA) biochemical recurrence (BCR). RESULTS In total, 91 patients were enrolled. The mean age and PSA were 64.8 years and 9.3 ng/dl, respectively. The median post-operative GS was 7. Low AMH blood levels were correlated with higher post-operative GS (p = 0.001), as well as with PSA BCR (p = 0.043). With pT3 disease, only albumin was (negatively) correlated (p = 0.008). ROC analysis showed that AMH is a good predictor of BCR (AUC 0.646, 95% CI 0.510-0.782, p = 0.043); a cutoff value of 3.06 ng/dl had a positive prognostic value of 71.4% and a negative prognostic value of 63.3% for BCR. Cox regression analysis showed that AMH is a statistically significant and independent prognostic marker for BCR (p = 0.013). More precisely, for every 1 ng/ml of AMH rise, the probability for PSA BCR decreases by 20.8% (HR = 0.792). Moreover, in Kaplan-Meier analysis, disease-free survival is more probable in patients with AMΗ ≥ 3.06 ng/ml (p = 0.004). CONCLUSIONS Low AMH blood levels were correlated with aggressive prostate cancer in this radical prostatectomy cohort of patients. Therefore, AMH could be a prognostic biomarker for the aggressiveness of the disease.
Collapse
Affiliation(s)
| | | | - Maria Stamou
- Harvard Reproductive Sciences Center, Massachusetts General Hospital, Boston, MA, USA
| | | | - Irini Mamali
- Endocrinology Department, Patras University Hospital, Patras, Greece
| | | | | | | | | |
Collapse
|
2
|
Zhou K, Zhang S, Wang Y, Cohen KB, Kim JD, Luo Q, Yao X, Zhou X, Xia J. High-quality gene/disease embedding in a multi-relational heterogeneous graph after a joint matrix/tensor decomposition. J Biomed Inform 2022; 126:103973. [PMID: 34995810 DOI: 10.1016/j.jbi.2021.103973] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 10/20/2021] [Accepted: 12/04/2021] [Indexed: 10/19/2022]
Abstract
MOTIVATION Node embedding of biological entity network has been widely investigated for the downstream application scenarios. To embed full semantics of gene and disease, a multi-relational heterogeneous graph is considered in a scenario where uni-relation between gene/disease and other heterogeneous entities are abundant while multi-relation between gene and disease is relatively sparse. After introducing this novel graph format, it is illuminative to design a specific data integration algorithm to fully capture the graph information and bring embeddings with high quality. RESULTS First, a typical multi-relational triple dataset was introduced, which carried significant association between gene and disease. Second, we curated all human genes and diseases in seven mainstream datasets and constructed a large-scale gene-disease network, which compromising 163,024 nodes and 25,265,607 edges, and relates to 27,165 genes, 2,665 diseases, 15,067 chemicals, 108,023 mutations, 2,363 pathways, and 7.732 phenotypes. Third, we proposed a Joint Decomposition of Heterogeneous Matrix and Tensor (JDHMT) model, which integrated all heterogeneous data resources and obtained embedding for each gene or disease. Forth, a visualized intrinsic evaluation was performed, which investigated the embeddings in terms of interpretable data clustering. Furthermore, an extrinsic evaluation was performed in the form of linking prediction. Both intrinsic and extrinsic evaluation results showed that JDHMT model outperformed other eleven state-of-the-art (SOTA) methods which are under relation-learning, proximity-preserving or message-passing paradigms. Finally, the constructed gene-disease network, embedding results and codes were made available. DATA AND CODES AVAILABILITY The constructed massive gene-disease network is available at: https://hzaubionlp.com/heterogeneous-biological-network/. The codes are available at: https://github.com/bionlp-hzau/JDHMT.
Collapse
Affiliation(s)
- Kaiyin Zhou
- Hubei Key Lab of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Sheng Zhang
- College of Science, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Yuxing Wang
- Hubei Key Lab of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Kevin Bretonnel Cohen
- School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
| | - Jin-Dong Kim
- Database Center for Life Science (DBCLS), Research Organization of Information and Systems (ROIS), Kashiwa, Tokyo, Japan
| | - Qi Luo
- College of Science, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Xinzhi Yao
- Hubei Key Lab of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Xingyu Zhou
- Hubei Key Lab of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, Hubei, China
| | - Jingbo Xia
- Hubei Key Lab of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, Hubei, China.
| |
Collapse
|
3
|
Bertho S, Neyroud AS, Brun T, Jaillard S, Bonnet F, Ravel C. Anti-Müllerian hormone: A function beyond the Müllerian structures. Morphologie 2021; 106:252-259. [PMID: 34924282 DOI: 10.1016/j.morpho.2021.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 11/11/2021] [Accepted: 11/14/2021] [Indexed: 10/19/2022]
Abstract
The anti-Müllerian hormone (AMH) is a heterodimeric glycoprotein belonging to the TGFb superfamily implicated in human embryonic development. This hormone was first described as allowing regression of the epithelial embryonic Müllerian structures in males, which would otherwise differentiate into the uterus and fallopian tubes. It activates a signaling pathway mediated by two transmembrane receptors. Binding of AMH to its receptor induces morphological changes leading to the degeneration of Müllerian ducts. Recently, new data has shown the role played by this hormone on structures other than the genital tract. If testicular AMH expression decreases in humans over the course of a lifetime, synthesis may persist in other tissues in adulthood. The mechanisms underlying its production have been unveiled. The aim of this review is to describe the different pathways in which AMH has been identified and plays a pivotal role.
Collapse
Affiliation(s)
- S Bertho
- CHU Rennes, Département de Gynécologie-Obstétrique-Reproduction-CECOS, 35000 Rennes, France.
| | - A S Neyroud
- CHU Rennes, Département de Gynécologie-Obstétrique-Reproduction-CECOS, 35000 Rennes, France; Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - T Brun
- CHU Rennes, Département de Gynécologie-Obstétrique-Reproduction-CECOS, 35000 Rennes, France
| | - S Jaillard
- CHU Rennes, Département de Gynécologie-Obstétrique-Reproduction-CECOS, 35000 Rennes, France; Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| | - F Bonnet
- CHU Rennes, Service d'Endocrinologie, 35000 Rennes, France
| | - C Ravel
- CHU Rennes, Département de Gynécologie-Obstétrique-Reproduction-CECOS, 35000 Rennes, France; Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France
| |
Collapse
|
4
|
Verdiesen RMG, van Gils CH, Stellato RK, Verschuren WMM, Broekmans FJM, de Kat AC, van der Schouw YT, Onland-Moret NC. Anti-Müllerian Hormone Levels and Risk of Cancer in Women. Maturitas 2020; 143:216-222. [PMID: 33308632 DOI: 10.1016/j.maturitas.2020.10.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 10/11/2020] [Accepted: 10/25/2020] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To examine if age-specific anti-Müllerian hormone (AMH) levels are associated with cancer risk; and to investigate if age-related AMH trajectories differ between women who develop cancer and women who do not. More specifically, we examined associations with breast cancer, cancers in other tissues expressing AMH receptor AMHR2, and cancers in non-AMHR2-expressing tissues. STUDY DESIGN We included longitudinal data from 3025 women in the prospective Doetinchem Cohort Study. Cox proportional hazards models were used to assess the association of baseline age-specific AMH tertiles with cancer. We applied linear mixed models to compare age-related AMH trajectories between women who were diagnosed with cancer and women who were not. MAIN OUTCOME MEASURES Cancer (n = 385; 139 breast cancers, 112 cancers in other AMHR2-expressing tissues, 134 cancers in non-AMHR2-expressing tissues). RESULTS Overall, baseline age-specific AMH levels were not associated with cancer risk, although in women ≤ 40 years an increased risk was suggested for breast cancer (HRT2:T1 = 2.06, 95%CI = 0.95-4.48; HRT3:T1 = 2.03, 95%CI = 0.91-4.50). Analysis of age-related AMH trajectories suggested that AMH levels were higher at younger ages and declined faster in women who were diagnosed with cancer compared with women who were not, but our results did not provide evidence for actual differences in trajectories. CONCLUSIONS Our results did not provide evidence for an association between age-specific AMH levels and age-related trajectories and risk of cancer. However, effect estimates for breast cancer were in line with risk-increasing effects found in previous studies.
Collapse
Affiliation(s)
- Renée M G Verdiesen
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Carla H van Gils
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Rebecca K Stellato
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - W M Monique Verschuren
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Center for Nutrition, Prevention, and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
| | - Frank J M Broekmans
- Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Annelien C de Kat
- Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Yvonne T van der Schouw
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - N Charlotte Onland-Moret
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
| |
Collapse
|